Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Anemia
Interventions: ferumoxytol or oral iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 13
States / cities: Phoenix, Arizona • Tempe, Arizona • New Haven, Connecticut + 10 more

Conditions: Anemia, Iron Deficiency
Interventions: Ferrous sulphate drops with vitamins A, D, and C, Ferrous fumarate sprinkles with vitamins and minerals; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Months to 7 Months
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Anaemia
Interventions: Daprodustat (GSK1278863), Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 49
States / cities: Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Bevacizumab (Avastin®); Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions: Ferric Citrate; Drug
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Healthy Volunteers
Interventions: Iron Sucrose; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Anemia
Interventions: ferumoxytol or placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 41
States / cities: Mobile, Alabama • Phoenix, Arizona • Mountain View, California + 36 more

Conditions: Healthy Volunteers
Interventions: AKB-6548, Ferrous Sulfate; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4; Other · Drug
Lead sponsor: D. Walter Wray; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Miami Springs, Florida

Conditions: Iron-deficiency, Pregnancy Anemia, Obesity
Interventions: Jarrow Formulas Oral Bovine Lactoferrin Supplement; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic
Interventions: Olaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease, Thalassemia, Marrow Aplasia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions: Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 28
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more

Conditions: Iron Overload, Sickle Cell Disease, Other Anemias
Interventions: Deferiprone; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 3 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Oakland, California • Ann Arbor, Michigan • Detroit, Michigan + 2 more

Conditions: Iron
Interventions: Ferrous sulfate, IHAT, Aspiron, Placebo; Dietary Supplement · Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Trauma, ICU Anemia
Interventions: Iron sucrose, Placebo; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • New York, New York + 3 more

Conditions: Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glucose Intolerance, Insulin Resistance, Iron Metabolism
Interventions: Blood Donation; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Renal Failure Chronic Requiring Hemodialysis
Interventions: Soluble Ferric Pyrophosphate (SFP), Standard dialysate; Drug · Device
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more

Conditions: Myelodysplastic Syndromes
Interventions: FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software; Drug · Other · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: CoA-Z, Placebo; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 3 Months to 89 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Kidney Disease, Anemia of Chronic Disease
Interventions: Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Restless Legs Syndrome (RLS)
Interventions: Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more

Search by objective public record fields.

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

Adherence With Iron Sprinkles Among High-Risk Infants

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer

A Crossover Safety Study of Ferumoxytol Versus Placebo

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

: Vascular Function in Health and Disease

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Genes Influencing Iron Overload State

Stroke With Transfusions Changing to Hydroxyurea

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers

IV Iron for the Anemia of Traumatic Critical Illness

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Iron and Insulin Resistance in Overweight and Obese Humans

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia